CN1480193A - Kuhseng targeting preparation and its preparing method - Google Patents
Kuhseng targeting preparation and its preparing method Download PDFInfo
- Publication number
- CN1480193A CN1480193A CNA031398731A CN03139873A CN1480193A CN 1480193 A CN1480193 A CN 1480193A CN A031398731 A CNA031398731 A CN A031398731A CN 03139873 A CN03139873 A CN 03139873A CN 1480193 A CN1480193 A CN 1480193A
- Authority
- CN
- China
- Prior art keywords
- radix sophorae
- sophorae flavescentis
- preparation
- targeting preparation
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
A target medicine is prepared from flavescent sophora root and superfine particles as carrier. Its advantages are high target performance and biologic utilization rate, and no toxic by-effect to normal cells.
Description
Technical field
The present invention relates to traditional Chinese medicine technology, a kind of specifically Radix Sophorae Flavescentis targeting preparation and preparation method thereof.
Background technology
Radix Sophorae Flavescentis derives from the root of leguminous plant Radix Sophorae Flavescentis (Sophora flavescens Ait), Herba Sophorae alopecuroidis (S.aloprcuroides L.) whole plant, root of subprostrate sophora (S.subprostrata Chur.Et T.Chen) root, mamani (S.chrysophylla Seem.) bark, kowhai (S.tetraptera F.Mill) timber, bark, Japanese Radix Sophorae Tonkinensis (Euchresta japoni-ca Benth.) aerial parts.Have multiple pharmacological effect, be widely used in digesting, the treatment of cardiovascular, nervus centralis, breathing, parasitic disease etc.In recent years, Radix Sophorae Flavescentis and effective ingredient Radix Sophorae Flavescentis alkaloid thereof are in treatment B virus type hepatitis, improve hepatocyte function, anti-hepatic fibrosis, the curative effect of immune adjusting and anti-tumor aspect has been caused people's attention, as the medicine of anti-HBV pharmacological basis is widely arranged with matrine, become treatment viral hepatitis, antineoplastic medicine commonly used.
Hepatitis B virus infection is a worldwide hygienic issues.The hepatitis B virus infection person of quite a few, particularly juvenile stage HBV the infected can move and be transformed into chronic hepatitis, liver cirrhosis or hepatocarcinoma.China is the district occurred frequently of hepatitis B, and the prevention of hepatitis B and treatment are difficult problems pharmaceutically.Although Hepatitis B virus vaccine can prevent it to infect, in the face of the huge infection population of number, about 5% to vaccine not the hepatitis B virus mutant of responder and the possible vaccine-induced immunity of escape all press for effective treatment means.To chronic hepatitis B the infected's treatment, interferon-alpha is present the most frequently used medicine, but its effective percentage not high (being about 30%-40%), toleration is poor.Nucleoside analog is to suppress duplicating of hepatitis B virus by suppressing synthesizing of hepatitis B virus minus-strand dna, but the state of an illness of Most patients can recur after the drug withdrawal, and long-term prescription can cause the appearance of persister.Protocols in Molecular Biology treatment hepatitis B still is in the experimentation stage at present, has certain therapeutic effect in experiment.Some other Therapeutic Method comprises that immunomodulator and curative vaccine still are in the exploration at present.Western medicine adopts chemotherapy mostly, distributes at whole body after the administration, and also injuring normal cell when killing and wounding cancerous cell produces bigger untoward reaction.Make patient's temporary transient drug withdrawal of having to, the chance of delay treatment.The treatment by Chinese herbs hepatic disease has bigger advantage, and low this understanding of the toxic and side effects of Chinese medicine is accepted by people just gradually.But the main cause that this obstinate fort is not captured except the pharmacological action of medicine itself, is exactly medicine not to be delivered to effectively in the diseased region and cell of liver, and promptly medicine lacks the liver target even do not have targeting.
Summary of the invention
The objective of the invention is at the deficiencies in the prior art part, a kind of targeting preparation that contains the Chinese medicine Radix Sophorae Flavescentis is provided.Be applied in the body, utilize interior physics of human body and physiological action these drug microparticles dispersions can be gathered in positions such as liver, spleen, lymph selectively, concentrated these positions that are sent to of contained medicine are discharged and the performance curative effect, make it have the specificity of pharmacologically active, can increase directivity and the anelasticity of medicine to target tissue, thereby the raising bioavailability of medicament reduces medicine to Normocellular toxic and side effects.
The present invention also aims to provide the preparation method of described Radix Sophorae Flavescentis targeting preparation.
Radix Sophorae Flavescentis targeting preparation of the present invention comprises the ultra micron thing carrier of Radix Sophorae Flavescentis, inclusion Radix Sophorae Flavescentis.
Radix Sophorae Flavescentis and ultra micron thing carrier amount ratio are 50～600: 100～10000 weight portions.
Described Radix Sophorae Flavescentis comprises wherein one or more mixture of Radix Sophorae Flavescentis effective site, matrine, oxymatrine.
Described ultra micron thing carrier comprises microsphere, millimicro ball, liposome and magnetic preparation, is made by medical macromolecular materials and additives.
Described medical material comprises wherein one or more mixture such as macromolecular material such as polyesters, polymeric anhydride, amino acid polymer class, poly-polysaccharide and ethyl cellulose, polyvinyl alcohol and macromolecular material such as cholesterol, fabaceous lecithin, lecithin.
Described polyester comprises the positive butyl ester of alpha-cyanoacrylate, paracyanogen base alkyl acrylate or Polyisobutyl cyanoacrylate, the copolymer of polylactic acid, polylactic acid and Polyethylene Glycol, lactic acid-hydroxyacetic acid copolymer etc.
Described amino acid polymer class comprises albumin, gelatin, globulin, enzyme, polypeptide etc.
Described poly-polysaccharide mainly contains starch, glucosan, poly-chitose, arabic gum etc.
Used additives comprise the stabilizing agent of stereoscopic stable agent, emulsifying agent, raising zeta potential, the caffolding agent of making lyophilized injectable powder and magnetic material.Wherein the stereoscopic stable agent has dextran-70, pluronic, beta-schardinger dextrin-, Tweens (comprising tween 80, Tween-40 etc.), and emulsifying agent has lecithin, fabaceous lecithin etc.The stabilizing agent that improves zeta potential has sodium chloride, sodium nitrite, sodium sulfate, sodium thiosulfate, sodium pyrosulfite etc.The caffolding agent of making lyophilized injectable powder has mannitol, glucose, lactose etc.The magnetisable material material comprises that straight iron powder, carbonyl iron, magnetic iron ore are (as Fe
3O
4), ferrocobalt etc.Solvent for use comprises one or more mixture in water for injection, methanol, dichloromethane, chloroform, ether, injection Oleum Gossypii semen, the injection corn wet goods.
Described preparation comprises injection, capsule or tablet etc.
Radix Sophorae Flavescentis targeting preparation of the present invention is different with existing Kushen ', and the injection that contains Radix Sophorae Flavescentis that existing market is sold consists of flavescent sophora medicinal, solvent and cosolvent.
Ingredient of the present invention also comprises the ultra micron thing carrier that is formed by the high-molecular bone frame material except that Radix Sophorae Flavescentis raw material (comprising Radix Sophorae Flavescentis effective site, matrine, oxymatrine).Their formed preparation forms are not simple solution, but microsphere, millimicro ball, liposome and magnetic preparation that medicine and high polymer monomer material inclusion are formed, and can form multiple dosage forms such as injection, capsule, tablet.Also different on this external model of action, after the existing preparation that contains Radix Sophorae Flavescentis entered human body, except that pathological tissues absorbed, normal organ tissue also had absorption in the body, so dosage is big, side effect big, therapeutic effect is poor.And Radix Sophorae Flavescentis targeting preparation of the present invention has following model of action: (1) targeting: the influence that this dosage form is easy to be subjected to reticuloendothelial system in vivo is by macrophage phagocytic, and distribution of specific can improve the local valid density of medicine, reduces the whole body toxic and side effects.(2) slow-releasing: the drug release of microsphere parcel can be controlled and reached long-acting with suitable method, reduces dosage and medication number of times, changes the medicine peak valley phenomenon, and the blood drug level of medicine can be kept the long period.(3) strengthen medicine stability: some have parcel and the protective effect of the medicine of first pass effect by macromolecular material, have avoided medicine in vivo by rapid metabolism, but discharge medicine after arriving the target area.Thereby increased drug safety.
The method that the present invention prepares described Radix Sophorae Flavescentis targeting preparation microsphere (comprising the millimicro ball) comprises:
---with the Radix Sophorae Flavescentis material dissolution, adjust pH to 2～3 add medical macromolecular materials, stir the back adjust pH to neutral;
---the above-mentioned solution of sucking filtration obtains microsphere (millimicro ball);
---make preparation.
The Liposomal formulation preparation method of preparation Radix Sophorae Flavescentis targeting preparation is
---with Radix Sophorae Flavescentis raw material and medical an amount of fabaceous lecithin, cholesterol, be dissolved in the organic solvents such as methanol;
---at ambient temperature, decompression rotation removes down and desolvate, and makes lipid form thin film at wall;
---add an amount of phosphatic buffer, carry out jolting, form big multilamellar liposome, put and smash mixing in the high-speed tissue mashing machine to pieces, place the back and cross 0.45 μ m microporous filter membrane, be the even suspension of milky.
The magnetic formulation preparation method of preparation Radix Sophorae Flavescentis targeting preparation is
---Radix Sophorae Flavescentis raw material and high-molecular bone frame material, magnetic material are added water make suspension and add in the Oleum Gossypii semen;
---with the ultrasonic low temperature homogenize of above-mentioned suspension, drop in 110 ℃～165 ℃ the Oleum Gossypii semen again, constantly stir, centrifugalize is promptly.
---make preparation.
Calculate dosage according to prescription, the prepared targeting millimicro ball that contains the Chinese medicine Radix Sophorae Flavescentis can be made intravenous fluid, also can adjust dosage according to prescription, the targeting millimicro ball that contains the Chinese medicine Radix Sophorae Flavescentis with utilization is tablet or capsule adjuvant in addition, makes millimicro ball targeting tablet or the capsule formulation that contains the Chinese medicine Radix Sophorae Flavescentis by the pharmacy common process.
The present invention compared with prior art has following advantage
(1) improves therapeutic effect, reduce toxic and side effects.The most outstanding characteristics are medicine can be transported to the target area to greatest extent after the targeting preparation administration, make medicine exceed the several times of conventional formulation and even hundreds of times in target area concentration, and therapeutic effect obviously improves.Normal structure abundance owing to medicine reduces than conventional formulation simultaneously, so the toxic and side effects of medicine and untoward reaction meeting obviously alleviate, it is played a role on the cell of pathological tissues or subcellsular level, and normal structure is not had too much influence, thereby reach the raising curative effect, reduce the purpose of toxic and side effects.
(2) adopt the drug release of macromolecular material parcel to be controlled and reach long-acting, reduce the medication number of times, change the medicine peak valley phenomenon with suitable method.By the parcel and the protective effect of macromolecular material, can avoid the first pass effect of liver simultaneously, prevent that medicine is damaged by rapid metabolism in vivo, but discharge medicine after arriving the target area.
(3) construction cycle weak point, production technology is reasonable in design, is fit to suitability for industrialized production.Simultaneously traditional Chinese medicine is made modern targeting preparation, meet the needs of Chinese medicine urgency, serious symptom.Therefore developing this type of preparation, is the hope place of China's medicinal industry development, is the legal inevitable approach that enters international medical market.
The specific embodiment
Embodiment 1: Radix Sophorae Flavescentis targeting PBCA millimicro ball injection (by making 1000ml)
Prescription:
Matrine: 200g
The positive butyl ester of alpha-cyanoacrylate: 100ml
Sodium pyrosulfite: 25g
Dextran-70: 100g
Preparation method:
Matrine 200g mixed with sodium pyrosulfite 25g, dextran-70 100g place beaker, add the dissolving of injection water, with 0.1mol/L dilute hydrochloric acid adjust pH 2, be transferred in the beaker, slowly add the positive butyl ester of alpha-cyanoacrylate under the magnetic agitation, after stirring 3h at ambient temperature again,, use G with 0.1mol/L dilute sodium hydroxide adjust pH to 7
3The sintered glass funnel sucking filtration adds water for injection to 1000ml.Promptly get Radix Sophorae Flavescentis targeting PBCA millimicro ball injection.
Embodiment 2: Radix Sophorae Flavescentis targeting polylactic acid millimicro ball
Prescription:
Oxymatrine: 100g
Polylactic acid: 50ml
Dichloromethane: 500ml
Polyvinyl alcohol: 50ml
Preparation method:
At first polylactic acid is dissolved in the volatile organic solvent dichloromethane, is mixed with 10% solution,
Oxymatrine 100mg is suspended in this solution.Then the mixture that obtains is suspended in
In 1% the poly-vinyl alcohol solution that stirs, constantly stir, solvent is waved from established microdroplet
Send to the greatest extent, centrifugally obtain solid-state medicine carrying microballoons, collect microsphere and use deionized water wash, filtration,
Vacuum drying promptly under the room temperature.
Embodiment 3: oxidation Radix Sophorae Flavescentis target liposomes injection (by making 1000ml)
Prescription:
Oxymatrine: 200g
Fabaceous lecithin: 50g
Cholesterol: 125g
Methanol and chloroform: 50ml
Preparation method:
The fabaceous lecithin of recipe quantity, cholesterol, matrine etc. are dissolved in the mixed solvent of 50ml methanol and chloroform, pour in the rotary film evaporator, in temperature is 35 ℃, removes organic solvents such as methanol and chloroform under the vacuum decompression condition, makes it form uniform dry film on the bottle wall; Add phosphatic buffer 50ml, carry out jolting, form big multilamellar liposome after, put in the high-speed tissue mashing machine, 12 000r/min * 2min * 4 time are placed the back and are crossed 0.45 μ m microporous filter membrane, are the uniform Radix Sophorae Flavescentis target liposomes of milky injection.
Embodiment 4: oxidation Radix Sophorae Flavescentis targeting Polyisobutyl cyanoacrylate millimicro ball injection (by making 1000ml) prescription:
Oxymatrine: 200g
Isobutylcyanoacrylate: 15ml
Sodium sulfite: 50g
Dextran-70: 120g
Preparation method: (1) blank Polyisobutyl cyanoacrylate millimicro ball preparation: take by weighing the stirring of 120g dextran-70 it is dissolved in the 600ml water for injection, add sodium sulfite 50g dissolving again, regulate PH to 3 with glacial acetic acid, add water to 700ml, adopt magnetic agitation (100 rev/mins), slowly add the 15ml isobutylcyanoacrylate, continue to stir 5h, obtain milky blank millimicro ball.(2) precision takes by weighing the matrine of recipe quantity, with 100ml water for injection jolting dissolving, under 600 rev/mins mixing speed, lentamente barren Polyisobutyl cyanoacrylate millimicro globule is gone in the solution of matrine, add the injection water after waiting to drip off to 1000ml, continue to stir 3h promptly.
Embodiment 5: Radix Sophorae Flavescentis targeting PBCA lyophilized injectable powder
Prescription:
Oxymatrine: 200g
The positive butyl ester of alpha-cyanoacrylate: 100ml
Sodium pyrosulfite 50g
Dextran-70 100g
Glucose: 50g
Preparation method:
The recipe quantity medicine mixed with sodium pyrosulfite 50g, dextran-70 100g place beaker, add the dissolving of injection water, with 0.1mol/L dilute hydrochloric acid adjust pH 2, be transferred in the beaker, slowly add the positive butyl ester of alpha-cyanoacrylate with microsyringe under the magnetic agitation, after stirring 3h under 30 ℃ of conditions,, use G again with 0.1mol/L dilute sodium hydroxide adjust pH to 7
3The sintered glass funnel sucking filtration promptly gets Radix Sophorae Flavescentis targeting PBCA nanocapsule injection.The glucose of adding 10% is as timbering material, and lyophilized injectable powder is made in lyophilization, promptly.
Embodiment 6: Radix Sophorae Flavescentis targeting PBCA microsphere (by making 1000ml)
Prescription:
Oxymatrine: 200g
The positive butyl ester of alpha-cyanoacrylate: 70ml
Sodium sulfate 20g
Sodium chloride 15g
Dextran-70 150g
Preparation method:
Dextran-70 150g and sodium chloride 15g are dissolved in 450 milliliters of waters for injection, transfer pH value to 1.8 with dilute hydrochloric acid, slowly add the positive butyl ester of alpha-cyanoacrylate under the magnetic agitation, after the stirring at room 3 hours, add oxymatrine 200g, continue to stir after 1 hour, added the sodium sulfate restir 2 hours, regulate pH value to 7 then, the microporous filter membrane that gained solution is crossed 0.4 μ m promptly.Add at last the injection water to 1000ml promptly.Embodiment seven: oxymatrine magnetic preparation
Prescription: oxymatrine: 200mg
Albumin: 50mg
Ultra micro Fe
3O
4Ferromagnetic particles: 120mg
Oleum Gossypii semen: 10ml
Water for injection: 5ml
Ether: 20ml
Normal saline: 2ml
Tween 80: 0.4ml
Preparation method:
Medicine and albumin 50mg, ultra micro Fe with recipe quantity
3O
4Ferromagnetic particles adds and adds in the 2ml Oleum Gossypii semen after the injection water is made suspension, stirred (2500 rev/mins) 10 minutes, use the ultrasonic low temperature homogenize, again above-mentioned suspension is dropped in the Oleum Gossypii semen of 110 ℃～165 ℃ of heating, under 2500 rev/mins mixing speed, constantly stir, 160 ℃ are incubated 10 minutes, continue to be stirred to room temperature, add ether defatting, centrifugal (3000 rev/mins), discard oil phase, the normal saline that reuse contains 0.2% tween 80 disperses, and becomes uniform injection promptly through ultrasonic Treatment.
Claims (10)
1, a kind of Radix Sophorae Flavescentis targeting preparation is characterized in that comprising the ultra micron thing carrier of Radix Sophorae Flavescentis, inclusion Radix Sophorae Flavescentis, and described Radix Sophorae Flavescentis and ultra micron thing carrier amount ratio are 50～600: 100～10000 weight portions.
2, described Radix Sophorae Flavescentis targeting preparation according to claim 1 is characterized in that Radix Sophorae Flavescentis comprises wherein one or more mixture of Radix Sophorae Flavescentis effective site, matrine, oxymatrine.
3, described Radix Sophorae Flavescentis targeting preparation according to claim 1, it is characterized in that described ultra micron thing carrier is a microsphere, or millimicro ball, or liposome, or magnetic dosage form, make by medical material and additives, described medical material comprises macromolecular material such as polyesters, polymeric anhydride, the amino acid polymer class, poly-polysaccharide and ethyl cellulose, polyvinyl alcohol, and macromolecular material such as cholesterol, fabaceous lecithin, lecithin is one or more mixture wherein, and described additives comprise the stereoscopic stable agent, emulsifying agent, improve the stabilizing agent of zeta potential, make the caffolding agent and the magnetic material of lyophilized injectable powder.
4, according to the described Radix Sophorae Flavescentis targeting preparation of claim 3, it is characterized in that described polyester comprises the positive butyl ester of alpha-cyanoacrylate, paracyanogen base alkyl acrylate or Polyisobutyl cyanoacrylate, copolymer, the lactic acid-hydroxyacetic acid copolymer of poly-carbon ester, polylactic acid, polylactic acid and Polyethylene Glycol.
5,, it is characterized in that described amino acid polymer class comprises wherein one or more mixture of albumin, gelatin, globulin, enzyme, polypeptide according to the described Radix Sophorae Flavescentis targeting preparation of claim 3.
6,, it is characterized in that described poly-polysaccharide mainly contains wherein one or more mixture of starch, glucosan, poly-chitose, arabic gum according to the described Radix Sophorae Flavescentis targeting preparation of claim 3.
7, according to the described Radix Sophorae Flavescentis targeting preparation of claim 3, it is characterized in that described stereoscopic stable agent is dextran-70, pluronic, beta-schardinger dextrin-or Tweens, emulsifying agent is lecithin or fabaceous lecithin, the stabilizing agent that improves zeta potential is sodium chloride, sodium nitrite, sodium sulfate, sodium thiosulfate or sodium pyrosulfite, and the caffolding agent of making lyophilized injectable powder is mannitol, glucose or lactose; The magnetisable material material comprises that straight iron powder, carbonyl iron, magnetic iron ore are (as Fe
3O
4) or ferrocobalt; Solvent for use comprises one or more mixture in water for injection, methanol, dichloromethane, chloroform, ether, injection Oleum Gossypii semen, the injection Semen Maydis oil.
8, the preparation method of the microsphere dosage form of the described Radix Sophorae Flavescentis targeting preparation of claim 1-7 is characterized in that comprising:
-with the Radix Sophorae Flavescentis material dissolution, adjust pH to 2～3 add medical macromolecular materials, stir the back adjust pH to neutral;
---the above-mentioned solution of sucking filtration obtains microsphere (millimicro ball);
---make preparation.
9, the preparation method of the liposome dosage form of the described Radix Sophorae Flavescentis targeting preparation of claim 1-7 is characterized in that comprising:
---Radix Sophorae Flavescentis raw material and medical an amount of fabaceous lecithin, cholesterol are dissolved in the organic solvents such as methanol;
---at ambient temperature, decompression rotation removes down and desolvate, and makes lipid form thin film at wall;
---add an amount of phosphatic buffer, carry out jolting, form big multilamellar liposome, put and smash mixing in the high-speed tissue mashing machine to pieces, place the back and cross 0.45 μ m microporous filter membrane, be the even suspension of milky.
10, the preparation method of the magnetic dosage form of the described Radix Sophorae Flavescentis targeting preparation of claim 1-7 is characterized in that comprising
---Radix Sophorae Flavescentis raw material and high-molecular bone frame material, magnetic material are added water make suspension and add in the Oleum Gossypii semen;
---with the ultrasonic low temperature homogenize of above-mentioned suspension, drop in 110 ℃～165 ℃ the Oleum Gossypii semen again, constantly stir, centrifugalize is promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031398731A CN1285347C (en) | 2003-07-18 | 2003-07-18 | Kuhseng targeting preparation and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031398731A CN1285347C (en) | 2003-07-18 | 2003-07-18 | Kuhseng targeting preparation and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1480193A true CN1480193A (en) | 2004-03-10 |
| CN1285347C CN1285347C (en) | 2006-11-22 |
Family
ID=34155134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031398731A Expired - Fee Related CN1285347C (en) | 2003-07-18 | 2003-07-18 | Kuhseng targeting preparation and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1285347C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014040366A1 (en) * | 2012-09-13 | 2014-03-20 | Zhao Junhong | Toxin expelling powder comprising root of buckwheat and preparation process thereof |
| CN105664173B (en) * | 2016-01-29 | 2018-09-04 | 山东省医学科学院药物研究所 | Permeable membrane small peptide-matrine and the preparation method and application thereof |
-
2003
- 2003-07-18 CN CNB031398731A patent/CN1285347C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014040366A1 (en) * | 2012-09-13 | 2014-03-20 | Zhao Junhong | Toxin expelling powder comprising root of buckwheat and preparation process thereof |
| CN105664173B (en) * | 2016-01-29 | 2018-09-04 | 山东省医学科学院药物研究所 | Permeable membrane small peptide-matrine and the preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1285347C (en) | 2006-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101028521A (en) | Oral colon positioning feed preparation based on electric spinning superfine nuclear fibre and its making method | |
| US9283190B2 (en) | Highly efficient and long-acting slow-release formulation of poorly soluble drugs and preparation method thereof | |
| CN1210065C (en) | Solid dispersion system of Pranlukast with improved dissolution, and the preparing method thereof | |
| CN100342914C (en) | Taxadol slow release nano-particle, its preparation method and application | |
| US8962017B2 (en) | Formulation of silymarin with high efficacy and prolonged action and the preparation method thereof | |
| CN1682883A (en) | Sarcandra solid dispersion and its preparing method | |
| US9023388B2 (en) | Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof | |
| CN1245398C (en) | Extraction technology of baicalein, medicinal composition and preparation technology of medicine | |
| CN1285347C (en) | Kuhseng targeting preparation and its preparing method | |
| CN1903183A (en) | Dispersion tablets of telbivudine and its prepn. method | |
| CN110251487B (en) | Preparation method and application of alcohol soluble protein nanoparticles for improving drug-loading rate and oral bioavailability of docetaxel | |
| CN1225464C (en) | Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine | |
| CN1608621A (en) | Fine bicyclic alcohol powder and oral bicyclic alcohol release controlling prepn | |
| CN101032462A (en) | Mexiletine Hydrochloride slow release reagent and preparing method thereof | |
| CN1235587C (en) | 9-nitrocamptothecin solid dispersant and preparation method | |
| CN1543943A (en) | Oral silybin sustained release agent and preparation thereof | |
| CN1748718A (en) | Fresh earthworm preparation with the functions of calming the liver and relieving convulsion, promoting blood circulation and removing obstruction in channels and its preparing method | |
| CN1759830A (en) | Enteric coated table of duloxetine, and preparation method | |
| Wang et al. | Preparation and in vitro/vivo evaluation of nano-liposomal form of febrifugine hydrochloride | |
| CN1295231C (en) | Bromo-dihydroartemisine | |
| CN113616780B (en) | Interferon alpha-2 b slow-release oral patch and preparation method thereof | |
| CN108785273B (en) | Entecavir capsule pharmaceutical composition and preparation method thereof | |
| CN1274295C (en) | Method for preparing oral slow/coutrolled release medicinal micro granule | |
| CN1480137A (en) | Osmotic pump type controlled release preparation of kurarinone and its preparing method | |
| CN1535972A (en) | New compound,its preparation method, medicine preparation using said compound as active component, its action and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061122 Termination date: 20120718 |